Friday, September 28, 2012
Alameda diagnostic test developer Singulex Inc. filed for an $86.25 million initial public offering Friday, promising a test to measure signs of heart disease at previously undetectable levels. Using the Jumpstart Our Business Startups, or JOBS, Act to qualify as an "emerging growth company," 15-year-old Singulex said in a filing with the Securities and Exchange Commission that its technology helps to earlier detect and monitor biomarkers of heart attacks, heart failure, stroke and other heart diseases.
Former Exelixis Inc. business development chief Fran Heller will join Bristol-Myers Squibb Co. as senior vice president of business development, the company said Friday.
Elan Corp. will shutter its South San Francisco drug discovery operations as it shifts the work into a new publicly held company. The Irish biotech company (NASDAQ: ELN), which this summer saw a high-profile experimental Alzheimer's drug crash in late-stage clinical trials, will have no drug discovery or preclinical drug development programs by Dec. 31, it said in a Securities and Exchange Commission filing this week. Closing the South San Francisco facilities, where most of Elan's roughly 400 employees are housed, will translate into $160 million to $180 million in employee severance costs, facilities costs and other restructuring charges, according to the Tuesday filing.
|Rigel's Don Payan (left) and Raul Rodriguez.|
AvidBiotics Corp.’s got a beef with its freshly minted multimillion-dollar deal with DuPont — and if things go as the small South San Francisco biotech company plans, it will have chicken and vegetables as well. AvidBiotics inked the deal Sept. 17 with DuPont’s health and nutrition business to develop a targeted protein to kill a strain of Escherichia coli, or E. coli, in meat processing plants. DuPont gave AvidBiotics upfront cash, took a minority stake in the eight-employee company and will pay all research and development costs.
Mission Bay roars to life: Biotechs, UCSF, residential developers jostle for space in S.F.'s newest neighborhood
|QB3's Reg Kelly.|
|Allopartis CEO Robert Blazej.|
Thursday, September 27, 2012
Medical products maker Abaxis Inc. will get $17.25 million in a settlement with Cepheid Inc. Sunnyvale-based Cepheid (NASDAQ: CPHD) will pay the money to Union City-based Abaxis (NASDAQ: ABAX) without admitting wrongdoing, but to "terminate all pending and future claims connected with the litigation." The dispute, in which both companies made claims and counterclaims, concerned several patents held by Abaxis over reagent and chemical compositions and processes.
The University of California, Berkeley, recently completed its $130 million, five-story Energy Biosciences Institute building. The 113,000-square-feet building at at 2151 Berkeley Way will feature modern facilities for scientific research, study and collaboration focusing on turning non-food crops into fuels. The structure, designed by SmithGroupJJRand built by Rudolph and Sletten, also comes with a myriad of green elements such as automated “smart” outside window shades, a lighting control system with building sensors, and an auto-adjusting air exchange system.
|Onyx CEO Tony Coles.|
Wednesday, September 26, 2012
|BioMarin's Jean-Jacques Bienaime.|
|Cytokinetics' Robert Blum.|
Tuesday, September 25, 2012
|UCSF Chancellor Susan Desmond-Hellmann.|
McKesson Corp., the San Francisco-based drug distribution and health care information technology giant, plans to build a $36.9 million distribution center in Frederick County, Virginia, for its medical-surgical division. The new center will create 205 jobs in the area, adding to the 1,000 McKesson jobs in Virginia.
Monday, September 24, 2012
|New Nodality President and CEO Laura Brege.|
Friday, September 21, 2012
|Astex CEO James Manuso.|
Avastin, the world's best-selling cancer drug from Swiss drug maker Roche, received a positive opinion Friday from a European Union group to treat a subset of ovarian cancer patients. The Committee for Medicinal Products for Human Use, or CHMP, essentially recommended that EU authorities approve Avastin in combination with the chemotherapy agents carboplatin and gemcitabine to treat women with recurrent, platinum-sensitive ovarian cancer, the company said Friday.
|David Jacobs of Silverstone Solutions.|
|Mission Bay (foreground).|
Thursday, September 20, 2012
Tuesday, September 18, 2012
|Medivation's David Hung.|
Monday, September 17, 2012
|Threshold CEO Barry Selick.|
|Complete Genomics' Cliff Reid.|
Friday, September 14, 2012
NovaBay Pharmaceuticals Inc. could receive investments of up to $5.5 million from a venture related to a Chinese drug company that signed a five-year marketing deal with NovaBay. Naqu Area Pioneer Pharma Co. Ltd. of Shanghai will pay the Emeryville-based company (NYSE MKT: NBY) $500,000 upfront to sell NovaBay's NeutroPhase skin and wound cleaner in Hong Kong, Macau, Taiwan, Singapore, Malaysia, Indonesia, Myanmar, Philippines, Thailand, Vietnam, Brunei, Cambodia and Laos. The commercial launches in select markets is expected by the end of this year, but others will have the product by 2014, NovaBay said Friday. NovaBay will receive up to $200,000 in milestone payments.
Impax Pharmaceuticals Inc. and partner Teva Pharmaceuticals USA Inc. settled litigation over a generic ADHD drug copied from one that belongs to Johnson & Johnson Inc. Hayward-based Impax (NASDAQ: IPXL) has a deal with Israel's Teva (NYSE: TEVA) to make a generic copy of Concerta, or methylphenidate hydrochloride extended release tablets. Teva Pharmaceuticals USA is based outside Philadelphia and also makes generic drugs. The two companies did not give details of their settlement with the two Johnson & Johnson (NYSE: JNJ) units, Janssen Pharmaceuticals Inc. and Alza Corp.
|Caribou Biosciences CEO Rachel Haurwitz.|
|David Levison of CardioDx.|
Thursday, September 13, 2012
|Napo CEO Lisa Conte.|
Tuesday, September 11, 2012
Monday, September 10, 2012
|Ben Harris, with son Rawdan and wife Rebecca.|
|Bayer's Chris Haskell.|
Friday, September 7, 2012
SFJ Pharmaceuticals Inc., a Pleasanton-based company formed to run clinical trials for large drug companies, will conduct a Phase III trial of Pfizer Inc.'s experimental lung cancer drug dacomitinib. Financial terms of the deal were not disclosed, but SFJ said it will fund and supervise the trial across sites in Asia and Europe that will help the world's largest drug maker (NYSE: PFE) submit dacomitinib for regulatory approval.
Genentech, 23andMe team up to discover if social media can point breast cancer researchers toward answers on Avastin
|Genentech's Philippe Bishop.|
|Proteus co-founder Dr. George Savage.|
|CytomX CEO Sean McCarthy.|
If twins know each other better than anyone else, leaders of Didimi Inc. are counting on the same holding true for our cells. One of the companies on the growing roster of the QB3 East Bay Innovation Center, Didimi is focusing on a way to regenerate insulin-producing islet cells — from a patient’s own or someone else’s cells — as a treatment for Type 1 diabetes. Call it a cellular do-over or a scientific version of “Groundhog Day” with some potentially stunning implications.
When Angela Elliot isn’t teaching aerobics to her colleagues, she’s out jogging with them on her lunch break. If she doesn’t show up, she feels guilty about it later. Elliott, a senior manager for Bayer Healthcare’s process validation group, is just one of many employees who lives up to the company’s motto of using science for a better life. The company’s focus on well-being has created a culture of health and fitness that encourages employees to encourage each other.
Jazz Pharmaceuticals will sell its women's heath business to specialty pharmaceutical company Meda for $95 million in cash. Jazz, which has an office in Palo Alto (NASDAQ:JAZZ) said in the release that the sale involves six products: Elestrin, Gastrocrom, Natelle One, AVC, Gesticare DHA and Urelle.
Thursday, September 6, 2012
They can't do it in people, but scientists think they can keep switchgrass "forever young" by inserting a new gene, thus making it more useful in creating biofuel. Geneticists from the University of California, Berkeley, and the U.S. Department of Agriculture did the work at the USDA's Plant Gene Expression Center in Albany. Sarah Hake, who runs the lab, and UC Berkeley's George Chuck inserted a new maize gene, called "Corngrass1" or Cg1, into Panicum virgatum, or switchgrass, thus keeping it in a "juvenile" state without flowers or seeds.
Thermo Fisher Scientific Inc., the Waltham, Mass.-based scientific instrument maker, plans to build out a new home in Fremont for its roughly 400 employees. Thermo Fisher confirmed that it bought 22 of 147 acres from Union Pacific that surround the Tesla Motors Inc. manufacturing plant. The company currently leases three facilities in Fremont that are within two miles of the parcel.
KaloBios Pharmaceuticals Inc. raised $10 million, with an option to borrow an additional $5 million, in a debt financing with MidCap Financial SBIC LP. South San Francisco-based KaloBios will use the money to advance clinical development of its monoclonal antibody drugs, including Phase II trials of its severe asthma drug and a treatment for cystic fibrosis patients, and for general corporate purposes.
Astex Pharmaceuticals Inc. inked a research collaboration with Cancer Research Technology Ltd. and the Institute of Cancer Research in London to discover and develop drug candidates for blood cancer caused by epigenetics. Dublin-based Astex (NASDAQ: ASTX) did not disclose the value of the deal or say how long the collaboration would last.
VistaGen Therapeutics Inc. restructured nearly $2.4 million of long-term debt with law firm Morrison & Foerster LLP as an investor bought a $750,000 note from the South San Francisco biotech company. VistaGen (OTCBB: VSTA), which is developing ways to incorporate human stem cells into research lab tests that can predict a drug's toxicity or help with drug discovery, said about $1.38 million of the debt to Morrison & Foerster is expected to be converted into restricted common stock at a price of $1 per share. It did not say how the remaining $1 million in debt would be restructured.
StemCells Inc. and three other research projects won a total of $63 million in funding Wednesday night from California's stem cell research funding agency. But the $20 million earmarked by the California Institute for Regenerative Medicine for StemCells (NASDAQ: STEM) -- the Newark company's second award in two months -- comes with a catch. StemCells must satisfy CIRM staff of "the company's ability to access the capital needed to fund the project."
Tuesday, September 4, 2012
OptiMedica Corp. has been granted U.S. Food and Drug Administration 510(k) market clearance for its "Catalys Precision Laser System" for single-plane and multi-plane cuts in the cornea during cataract surgery, according to a release.
Codexis Inc., a company that makes environmentally friendly chemicals, fuels and pharmaceutical processes, said Tuesday it will lay off 133 people. The layoffs are necessary because the Redwood City-based company is ending an agreement it had with Royal Dutch Shell Plc and will lose ongoing funding, a statement from the company said.
|Jonathan Sheena of Natera.|
|StemCells CEO Martin McGlynn.|